Cumberland Pharmaceuticals Inc.
CPIXCumberland Pharmaceuticals Inc. in brief
Cumberland Pharmaceuticals Inc. is a listed company in the Pharmaceutical industry, based in Nashville,, Tennessee, USA. Its market value was $65 M on 27 October 2026, which makes it the 20,341st largest listed company in the world and the 3,742nd largest in the USA on this site. In the year to December 2025 it had sales of $45 M and a net loss of $3 M. It employs about 93 people and A. J. Kazimi is its chief executive. Its largest product and service lines by sales in 2025 were Sancuso (27%), Kristalose (24%) and Vibativ (21%). Its shares trade under the symbol CPIX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc., is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. We are dedicated to our mission of working together to provide unique products that improve the quality of patient care.
Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by relatively small, targeted sales forces. We promote our approved products through our hospital, field and oncology sales divisions in the United States. We have also established a network of international partners with the needed regulatory and commercial capabilities to register and provide our medicines to patients in their countries.
From the company's annual report filed with the US SEC: read the report
Cumberland Pharmaceuticals Inc. timeline
- 2002
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2009
- 🔔· approximateInitial public offering on Nasdaq
- 2025
- 💰Record revenue of $45 millionFY2025, the highest of the 8 years on record.
Events of Cumberland Pharmaceuticals Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,828 (Jan 2020) · #4,126 (Jan 2021) · #4,763 (Jan 2022) · #5,066 (Dec 2022) · #5,150 (Jul 2023) · #4,253 (Jan 2024) · #2,130 (Mar 2026) · #3,356 (Aug 2026) · #3,473 (Oct 2026) · #3,746 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1.6×
- Price / book
- 2.6×
- Free cash flow yield
- 7.4%
- Net margin (TTM)
- -27.4%
- Operating margin
- -6.3%
- Return on equity
- -43.9%
- Liabilities / assets
- 68.1%
- Revenue growth
- +17.6%
- R&D / revenue
- 12.5%
- Revenue per employee
- $479 K
- Profit per employee
- $-31 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $45M | +17.6% | $-3M | $-3M | -6.4% |
| Dec 2024 | $38M | -4.2% | $-6M | $-6M | -17.1% |
| Dec 2023 | $40M | -5.9% | $-10M | $-6M | -15.9% |
| Dec 2022 | $42M | +16.7% | $-6M | $-6M | -13.3% |
| Dec 2021 | $36M | -3.9% | $-8M | $-4M | -9.8% |
| Dec 2020 | $37M | +8.9% | $-6M | $-3M | -8.9% |
| Dec 2019 | $34M | +17.2% | $-9M | $-4M | -10.3% |
| Dec 2018 | $29M | — | $-11M | $-7M | -23.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $5M | $0M | $5M | $-0.19 | — |
| Dec 2024 | $-1M | $0M | $-1M | $-0.46 | — |
| Dec 2023 | $6M | $0M | $6M | $-0.44 | — |
| Dec 2022 | $8M | $0M | $8M | $-0.38 | — |
| Dec 2021 | $6M | $0M | $6M | $-0.24 | — |
| Dec 2020 | $5M | $0M | $5M | $-0.22 | — |
| Dec 2019 | $3M | $0M | $3M | $-0.23 | — |
| Dec 2018 | $3M | $0M | $3M | $-0.45 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $2M (-73.9% on a year earlier), net income $78M. Trailing 12 months to Jun 2026.
SEC filings
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 26, 20268-KCurrent reportRegulation FD disclosure · Other events
- Oct 23, 20268-KCurrent reportOther events
- Sep 11, 20268-K/ACurrent report (amended)Shareholder vote
- Aug 28, 20268-KCurrent reportRegulation FD disclosure
- Aug 7, 202610-QQuarterly report · period to Jun 2026
- Aug 4, 20268-KCurrent reportResults of operations
- Jul 13, 20268-KCurrent reportOther events
- Jul 1, 20268-KCurrent reportMaterial agreement · Agreement ended · Acquisition or disposal completed · Directors or officers changed · Other events
- Jun 25, 20268-KCurrent reportShareholder vote
- May 8, 202610-QQuarterly report · period to Mar 2026
- May 5, 20268-KCurrent reportResults of operations
Official filings of Cumberland Pharmaceuticals Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $45 M
- Operating income
- $-3 M
- Net income
- $-3 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $77 M
- Total liabilities
- $52 M
- Total equity
- $25 M
As of December-2025
Top 35 institutional investors in Cumberland Pharmaceuticals Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Diversified Trust Co | 700,000 | New | 4.67% | $5 M | Nov 6, 2026 |
| 2 | Ikarian Capital, LLC | 503,153 | 0 (0.00%) | 3.36% | $4 M | Nov 16, 2026 |
| 3 | Renaissance Technologies LLC | 426,463 | -51,800 (-10.83%) | 2.85% | $3 M | Nov 12, 2026 |
| 4 | Vanguard Capital Management LLC | 379,478 | 0 (0.00%) | 2.53% | $3 M | Nov 13, 2026 |
| 5 | Dimensional Fund Advisors LP | 184,014 | -49,291 (-21.13%) | 1.23% | $1 M | Nov 4, 2026 |
| 6 | Boothbay Fund Management, LLC | 112,544 | 0 (0.00%) | 0.75% | $1 M | Nov 16, 2026 |
| 7 | Geode Capital Management, LLC | 108,820 | +407 (+0.38%) | 0.73% | $1 M | Nov 6, 2026 |
| 8 | Informed Momentum Co LLC | 94,948 | New | 0.63% | $1 M | Nov 16, 2026 |
| 9 | Jane Street Group, LLC | 80,592 | +23,851 (+42.03%) | 0.54% | $1 M | Nov 12, 2026 |
| 10 | Citadel Advisors LLC | 62,817 | -10,574 (-14.41%) | 0.42% | $0 M | Nov 16, 2026 |
| 11 | BlackRock, Inc. | 62,217 | -1,330 (-2.09%) | 0.42% | $0 M | Nov 13, 2026 |
| 12 | Bank of New York Mellon Corp | 58,458 | 0 (0.00%) | 0.39% | $0 M | Nov 5, 2026 |
| 13 | SEI Investments Co | 57,308 | New | 0.38% | $0 M | Nov 10, 2026 |
| 14 | Vanguard Fiduciary Trust Co | 54,909 | 0 (0.00%) | 0.37% | $0 M | Nov 13, 2026 |
| 15 | State Street Corp | 40,928 | +1,418 (+3.59%) | 0.27% | $0 M | Nov 12, 2026 |
| 16 | Bridgeway Capital Management, LLC | 25,789 | -411 (-1.57%) | 0.17% | $0 M | Nov 16, 2026 |
| 17 | UBS Group AG | 25,062 | -1,277 (-4.85%) | 0.17% | $0 M | Nov 10, 2026 |
| 18 | Northern Trust Corp | 24,739 | +2,786 (+12.69%) | 0.17% | $0 M | Nov 16, 2026 |
| 19 | Bailard, Inc. | 24,624 | 0 (0.00%) | 0.16% | $0 M | Oct 13, 2026 |
| 20 | Empowered Funds, LLC | 24,589 | New | 0.16% | $0 M | Nov 13, 2026 |
| 21 | Arrowstreet Capital, Limited Partnership | 23,822 | +3,570 (+17.63%) | 0.16% | $0 M | Nov 13, 2026 |
| 22 | HRT Financial LP | 23,325 | New | 0.16% | $0 M | Nov 13, 2026 |
| 23 | Magnolia Capital Advisors LLC | 20,000 | New | 0.13% | $0 M | Nov 16, 2026 |
| 24 | Prudential Financial Inc | 19,633 | New | 0.13% | $0 M | Nov 16, 2026 |
| 25 | Cresset Asset Management, LLC | 18,475 | -1,000 (-5.13%) | 0.12% | $0 M | Nov 16, 2026 |
Show all 35: investors 26 to 35
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Lantern Wealth Advisors, LLC | 13,500 | New | 0.09% | $0 M | Oct 22, 2026 |
| 27 | Vanguard Global Advisers, LLC | 4,500 | New | 0.03% | $0 M | Nov 13, 2026 |
| 28 | Morgan Stanley | 3,410 | +149 (+4.57%) | 0.02% | $0 M | Nov 13, 2026 |
| 29 | Tower Research Capital LLC (TRC) | 769 | +578 (+302.62%) | 0.01% | $0 M | Nov 16, 2026 |
| 30 | Capital Advisors, Ltd. LLC | 437 | 0 (0.00%) | 0.00% | $0 M | Oct 27, 2026 |
| 31 | Royal Bank Of Canada | 416 | New | 0.00% | $0 M | Nov 16, 2026 |
| 32 | Barclays PLC | 395 | +347 (+722.92%) | 0.00% | $0 M | Nov 6, 2026 |
| 33 | Osaic Holdings, Inc. | 240 | +40 (+20.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 34 | Wells Fargo & Company/mn | 100 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 35 | FMR LLC | 41 | +20 (+95.24%) | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Cumberland Pharmaceuticals Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 274,814 | $2 M | 1.8% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 99,719 | $1 M | 0.67% | <0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 49,950 | $0 M | 0.33% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 47,772 | $0 M | 0.32% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 47,968 | $0 M | 0.32% | <0.01% | +0.3% | May 31, 2026 |
| 🇺🇸 U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 37,593 | $0 M | 0.25% | <0.01% | −42% | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 28,898 | $0 M | 0.19% | 0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 Nationwide Bailard Small Cap Value FundNATIONWIDE FUND ADVISORS | 24,624 | $0 M | 0.16% | 0.13% | no change | Jul 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 25,000 | $0 M | 0.17% | 0.11% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 17,887 | $0 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 13,522 | $0 M | 0.09% | <0.01% | +9.1% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 11,327 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Targeted Value ETFDimensional Fund Advisors LP | 6,441 | $0 M | 0.04% | <0.01% | −83% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 6,355 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 4,933 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 4,945 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 4,562 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 3,702 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 3,758 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 2,780 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 2,800 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 2,517 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,991 | $0 M | 0.01% | <0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 AZL DFA U.S. Core Equity FundAllianz Investment Management LLC | 1,468 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Opportunities TrustJohn Hancock Variable Trust Advisers LLC | 956 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Core Equity FundJackson National Asset Management, LLC | 900 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional VA U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 700 | $0 M | <0.01% | <0.01% | −84% | Jul 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 363 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 331 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 29 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Cumberland Pharmaceuticals Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Martin S. Brown Jr.Director | Grant or award | +1,800 | $2.800 | $5 K | 10,300 | Form 4 |
| filed | Kenneth KrogulskiDirector | Grant or award | +1,800 | $2.800 | $5 K | 298,338 | Form 4 |
| filed | Caroline YoungDirector | Grant or award | +1,800 | $2.800 | $5 K | 35,109 | Form 4 |
| filed | Joseph C. GalanteDirector | Grant or award | +1,800 | $2.800 | $5 K | 63,656 | Form 4 |
| filed | James JonesDirector | Grant or award | +1,800 | $2.800 | $5 K | 46,863 | Form 4 |
| filed | Kenneth KrogulskiDirector | Grant or award | +4,000 | $2.800 | $11 K | 302,338 | Form 4 |
| filed | A. J. KazimiChairman and CEO, Director, 10% owner | Shares withheld for tax | -5,845 | $3.060 | $18 K | 5.70 M | Form 4 |
| filed | James JonesDirector | Small acquisition10b5-1 plan | +7 | $3.910 | $27 | 45,063 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Cumberland Pharmaceuticals Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2026 | Q3 2026 | $0.3M |
| Q2 2026 | Q2 2026 | $0M |
| Q1 2026 | Q1 2025 | $0.1M |
| Q4 2025 | Q4 2025 | $0M |
| Q3 2025 | Q3 2025 | $0M |
| Q2 2025 | Q2 2025 | $0M |
| Q1 2025 | Q1 2025 | $0.2M |
| Q4 2024 | Q4 2024 | $0.1M |
| Q3 2024 | Q3 2024 | $0.1M |
| Q2 2024 | Q2 2024 | $0.1M |
| Q1 2024 | Q1 2024 | $0.2M |
| Q4 2023 | Q4 2023 | $0.2M |
| Q3 2023 | Q3 2023 | $0.2M |
| Q2 2023 | Q2 2023 | $0.2M |
| Q1 2023 | Q1 2023 | $0.2M |
| Q4 2022 | Q4 2022 | $0.2M |
Trading halts
- 2026-04-23 13:33 UTC, code LUDP, resumed 13:38 UTC
- 2025-08-06 13:30 UTC, code LUDP, resumed 13:35 UTC
- 2025-02-05 15:08 UTC, code LUDP, resumed 15:13 UTC
- 2025-02-05 14:55 UTC, code LUDP, resumed 15:00 UTC
Fails to deliver
- : 736 shares at $4.35
- : 198 shares at $7.96
- : 40,330 shares at $7.18
- : 668 shares at $7.54
- : 689 shares at $7.49
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Cumberland Pharmaceuticals Inc. scorecard#
Passes 8 of the 24 checks that could be worked out: strongest in valuation (3 of 6), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Oct 27, 2026.
Valuation3 of 6
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.6×Price to book 2.6× against Pharmaceutical's median of 3.2×.
- ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Pharmaceutical's median of 3.5×.
- ✓Free cash flow yield above 5%7.4%Free cash flow is 7.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- ✗The price assumes slower growth than the last three years'7.8%The price assumes 7.8% a year for ten years; revenue grew 1.9% a year over the last three.
Growth2 of 6
- ✓Revenue grew in the newest year17.6%Revenue up 17.6% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years1.9%1.9% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median1.9%1.9% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✗Earnings per share grew in the newest year-0.19 vs -0.46Diluted EPS -0.19 in fiscal 2025 against -0.46 the year before (report's currency).
- ✓Net income higher than five years earlier-$3 M-$3 M in fiscal 2025 against -$3 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-6.3%-6.3% against Pharmaceutical's median of 1.8% (74 companies).
- ✗Return on equity above 15%-11.9%-11.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-6.3%-6.3% in fiscal 2025 against -13.6% in 2022.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities1.0×Current ratio 1.01 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-5.6×Operating income -5.6 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone0.72Z-score 0.72 (distress zone) for fiscal 2025.
Shareholder returns1 of 3
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year5.7%Diluted shares up 5.7% in fiscal 2025.
- ✗Dividends and buybacks above 3% of the market value0.4%Dividends and buybacks were 0.4% of the market value.
- ✓Free cash flow covers dividends and buybacks$5 MFree cash flow $5 M against $0 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Cumberland Pharmaceuticals Inc.'s statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -6.3% | 1.8% | |
| Net margin | -6.4% | -1.5% | |
| Return on equity | -11.9% | -0.9% | |
| Revenue growth, 3 years a year | 2.0% | 2.5% | |
| Revenue growth | 17.6% | 7.3% | |
| Free cash flow margin | 10.9% | 6.0% |
5of 8on the Piotroski tests of financial strength
- Net loss of $3 million, the 10th loss-making year in a row.
- The share count rose 5.7% in the year.
- Operating income covers the interest bill only -5.6 times.
- Receivables grew 45% while revenue grew 18%: customers are paying later, or sales were booked ahead of cash.
Cumberland Pharmaceuticals Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 45+17.6%100% | 38−4.3%100% | 40−5.9%100% | 42+16.7%100% | 36−3.9%100% | 37+8.9%100% | 34r48+17.2%100% | 29r41−28.7%100% | 41+24.6%100% | 33—100% | |
| Cost of revenue | 6.7+1.2%15.0% | 6.6+8.6%17.4% | 6.1−33.5%15.3% | 9.1+3.5%21.7% | 8.8+1.8%24.5% | 8.7+16.6%23.1% | 7.4r8.8+23.3%21.6% | 6.0r7.4−18.4%20.5% | 7.4+23.7%17.9% | 6.0—18.0% | |
| Research and development | 5.6+15.6%12.5% | 4.8−17.4%12.7% | 5.8−12.8%14.8% | 6.7+17.7%15.9% | 5.7−1.5%15.8% | 5.8−15.9%15.4% | 6.9r6.5−9.3%20.0% | 7.6r7.3+77.0%25.8% | 4.3r3.9+34.2%10.4% | 3.2—9.7% | |
| Selling and marketing | 19+12.2%42.9% | 17−7.7%45.0% | 18+10.7%46.7% | 17+11.0%39.7% | 15+1.7%41.7% | 15−3.4%39.4% | 15r21+9.1%44.4% | 14r20−34.8%47.7% | 21+47.7%52.2% | 15—44.1% | |
| General and administrative | 12+7.4%26.8% | 11+4.5%29.4% | 11+4.6%26.9% | 10+4.1%24.2% | 9.8−4.1%27.2% | 10+2.2%27.2% | 10.0r10−1.7%29.0% | 10r10+5.2%34.6% | 9.7r10+12.7%23.5% | 8.6—25.9% | |
| Total costs and expenses | 47+6.8%106% | 44−9.8%117% | 49+2.9%124% | 48+9.3%114% | 44−0.4%121% | 44+0.3%117% | 44r51+7.8%127% | 41r48−10.4%138% | 45+31.3%110% | 34—104% | |
| Operating income | −2.8—−6.3% | −6.4—−17.0% | −9.6—−24.2% | −5.7—−13.6% | −7.7—−21.3% | −6.4—−17.0% | −9.3r−3.6—−27.0% | −11r−7.4—−38.1% | −4.1—−9.9% | −1.4—−4.3% | |
| Interest and finance income | 0.5+42.5%1.1% | 0.3+16.6%0.9% | 0.3+192%0.7% | 0.1+277%0.2% | 0.0−65.4%0.1% | 0.1−69.0%0.2% | 0.2−56.9%0.7% | 0.6+88.6%1.9% | 0.3+46.3%0.7% | 0.2—0.6% | |
| Interest expense and finance costs | 0.5−18.1%1.1% | 0.6−9.3%1.6% | 0.7+14.0%1.7% | 0.6+498%1.4% | 0.1−62.8%0.3% | 0.3+7.1%0.7% | 0.2+25.7%0.7% | 0.2+111%0.7% | 0.1−12.7%0.2% | 0.1—0.3% | |
| Share of profit of associates | −0.0—−0.0% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Income before tax | −2.8—−6.3% | −6.5—−17.1% | −6.3—−15.9% | −5.6—−13.3% | −5.6—−15.5% | −6.6—−17.5% | −9.3r−3.6—−27.0% | −11r−7.0—−36.8% | −3.9—−9.4% | −1.3—−4.0% | |
| Income tax | 0.0—0.1% | −0.0−150%−0.1% | 0.0−33.5%0.1% | 0.1+97.3%0.2% | 0.0−37.6%0.1% | 0.1—0.1% | −0.1−577%−0.2% | 0.0−99.6%0.1% | 4.2—10.1% | −0.3—−1.0% | |
| Income from discontinued operations | — | — | — | 0−100%0.0% | 2.0−37.8%5.5% | 3.2−43.4%8.6% | 5.7+49.8%16.5% | 3.8—12.9% | — | — | |
| Net income including minority interests | −2.9—−6.4% | −6.4—−17.0% | −6.3—−16.0% | −5.7—−13.4% | −3.6—−10.0% | −3.4—−9.1% | −3.5—−10.3% | −7.0—−24.0% | −8.0—−19.6% | −1.0—−3.0% | |
| Minority interests' share of net income | −0.0−179%−0.1% | 0.0—0.1% | −0.1—−0.1% | −0.1—−0.2% | −0.1—−0.3% | −0.1—−0.2% | −0.0—−0.0% | −0.1—−0.3% | −0.1—−0.2% | −0.1—−0.2% | |
| Net income attributable to shareholders | −2.8—−6.4% | −6.5—−17.1% | −6.3—−15.9% | −5.6—−13.3% | −3.5—−9.7% | −3.3—−8.9% | −3.5—−10.3% | −7.0—−23.7% | −8.0—−19.4% | −0.9—−2.9% | |
| Earnings per share, basic | -0.19—— | -0.46—— | -0.44—— | -0.38—— | -0.24—— | -0.22—— | -0.23—— | -0.45—— | -0.50—— | -0.06—— | |
| Earnings per share, diluted | -0.19—— | -0.46—— | -0.44—— | -0.38—— | -0.24—— | -0.22—— | -0.23—— | -0.45—— | -0.50—— | -0.06—— | |
| Shares, weighted average (basic) | 15+5.6%— | 14−1.7%— | 14−1.8%— | 15−2.3%— | 15−1.7%— | 15−1.5%— | 15−1.4%— | 16−1.9%— | 16−2.0%— | 16—— | |
| Shares, weighted average (diluted) | 15+5.6%— | 14−1.7%— | 14−1.8%— | 15−2.3%— | 15−1.7%— | 15−1.5%— | 15−1.4%— | 16−1.9%— | 16−2.0%— | 16—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 11−36.3%14.9% | 18−2.0%23.8% | 18−7.3%22.4% | 20−26.9%21.3% | 27+9.2%32.0% | 25−12.3%25.7% | 28+1.0%27.0% | 28−38.5%24.8% | 45+31.6%48.7% | 35—36.9% | |
| Short-term investments | — | — | — | — | — | — | 0−100%0.0% | 8.3+77.4%7.4% | 4.7−70.1%5.0% | 16—16.7% | |
| Receivables | 17+44.8%22.1% | 12+19.9%15.5% | 9.8−25.9%11.9% | 13+91.4%14.2% | 6.9−44.4%8.1% | 12+57.5%12.8% | 7.9r9.8+0.2%7.5% | 7.8−6.6%7.0% | 8.4+14.5%9.0% | 7.3—7.8% | |
| Inventory | 0.0r6.2−99.3%0.0% | 4.0−13.2%5.3% | 4.6−53.3%5.6% | 9.9+17.0%10.6% | 8.4−20.8%10.0% | 11+19.9%11.0% | 8.9r9.4−26.6%8.5% | 12+79.3%10.7% | 6.7+25.4%7.2% | 5.4—5.8% | |
| Other current assets | 0.7r2.4−76.5%0.9% | 2.8−7.9%3.7% | 3.0−1.9%3.7% | 3.1−7.6%3.3% | 3.3+51.8%4.0% | 2.2−20.2%2.3% | 2.8−7.0%2.6% | 3.0−14.5%2.6% | 3.5+27.9%3.7% | 2.7—2.9% | |
| Current assets | 37+1.7%48.2% | 36+2.1%48.2% | 36−22.1%43.7% | 46+0.4%49.4% | 46−8.6%54.1% | 50−0.4%51.8% | 50−15.1%48.0% | 59−13.9%52.5% | 69+4.8%73.7% | 66—70.2% | |
| Property, plant and equipment | 0.3−4.6%0.3% | 0.3−24.6%0.4% | 0.4+29.5%0.4% | 0.3−35.8%0.3% | 0.4−22.9%0.5% | 0.6−23.2%0.6% | 0.7−3.0%0.7% | 0.8+45.8%0.7% | 0.5+13.9%0.6% | 0.5—0.5% | |
| Right-of-use (leased) assets | 5.8r8.3−6.4%7.5% | 6.2−7.5%8.2% | 6.7+27.9%8.2% | 5.2+410%5.6% | 1.0−49.5%1.2% | 2.0−31.5%2.1% | 3.0—2.8% | — | — | — | |
| Goodwill | 0.90.0%1.2% | 0.90.0%1.2% | 0.90.0%1.1% | 0.9+3.6%1.0% | 0.90.0%1.0% | 0.90.0%0.9% | 0.9+12.5%0.8% | 0.8—0.7% | 0—0.0% | — | |
| Other intangible assets | 0.1r14−99.7%0.1% | 18−20.5%23.8% | 23−26.1%27.6% | 31+27.7%32.9% | 24−14.8%28.4% | 28−9.1%29.1% | 31−8.1%29.6% | 34+56.9%29.9% | 21−3.2%23.0% | 22—23.7% | |
| Total assets | 77+1.6%100% | 76−7.6%100% | 82−12.0%100% | 93+10.0%100% | 84−12.4%100% | 96−7.7%100% | 105−7.2%100% | 113+20.9%100% | 93−0.2%100% | 93—100% | |
| Accounts payable | 19+33.4%24.2% | 14−0.9%18.4% | 14+29.7%17.2% | 11+12.2%11.6% | 9.6−28.0%11.4% | 13+34.0%13.9% | 10.0r12−9.9%9.6% | 11+23.5%9.8% | 9.0+11.7%9.6% | 8.0—8.6% | |
| Debt due within a year | 0−100%0.0% | 5.1—6.7% | 0—0.0% | — | — | — | — | — | — | — | |
| Current liabilities | 37+16.2%47.8% | 32+13.0%41.8% | 28−2.1%34.2% | 29+48.2%30.8% | 19−24.9%22.8% | 26+6.3%26.6% | 24−13.1%23.1% | 28+57.1%24.7% | 18+19.6%19.0% | 15—15.8% | |
| Lease liabilities (non-current) | 4.5−9.5%5.8% | 4.9−6.7%6.5% | 5.3+15.5%6.5% | 4.6+4995%4.9% | 0.1−91.5%0.1% | 1.1−49.0%1.1% | 2.1—2.0% | — | — | — | |
| Total liabilities | 52−1.4%68.1% | 53+1.0%70.2% | 53−7.8%64.2% | 57+36.1%61.3% | 42−15.6%49.6% | 50−7.2%51.4% | 53−6.4%51.1% | 57+94.9%50.7% | 29+44.5%31.4% | 20—21.7% | |
| Retained earnings | −27—−34.9% | −24—−31.7% | −17—−21.4% | −11—−12.1% | −5.6—−6.7% | −2.1−276%−2.2% | 1.2−74.5%1.2% | 4.7−59.5%4.2% | 12−37.1%12.6% | 19—19.9% | |
| Shareholders' equity | 25+8.9%32.4% | 23−22.8%30.2% | 30−18.4%36.2% | 36−15.3%39.0% | 43−8.9%50.7% | 47−8.1%48.7% | 51−8.5%48.9% | 56−12.9%49.6% | 64−12.5%68.8% | 73—78.4% | |
| Minority interests | −0.3—−0.4% | −0.3—−0.4% | −0.3—−0.4% | −0.3—−0.3% | −0.2—−0.3% | −0.1—−0.1% | −0.0—−0.0% | −0.3—−0.2% | −0.2—−0.2% | −0.1—−0.1% | |
| Total equity | 25+8.9%31.9% | 23−22.9%29.8% | 29−18.7%35.8% | 36−15.6%38.7% | 43−9.1%50.4% | 47−8.2%48.6% | 51−8.1%48.9% | 56−13.1%49.3% | 64−12.6%68.6% | 73—78.3% | |
| Total liabilities and equity | 77+1.6%100% | 76−7.6%100% | 82−12.0%100% | 93+10.0%100% | 84−12.4%100% | 96−7.7%100% | 105−7.2%100% | 113+20.9%100% | 93−0.2%100% | 93—100% | |
| Shares outstanding | 15+7.2%— | 14−1.2%— | 14−1.7%— | 14r14−2.6%— | 15−1.6%— | 15−1.8%— | 15r15−1.4%— | 15r16−3.7%— | 16r160.0%— | 16—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 4.1−15.4%9.3% | 4.9−0.7%12.9% | 4.9−7.4%12.5% | 5.3+15.7%12.7% | 4.6−3.0%12.8% | 4.7+7.8%12.7% | 4.4+47.7%12.8% | 3.0+12.7%10.2% | 2.6+10.5%6.4% | 2.4—7.3% | |
| Share-based compensation | 0.4+35.3%0.9% | 0.3−17.3%0.8% | 0.4−18.4%0.9% | 0.4−39.7%1.1% | 0.7−29.1%2.1% | 1.0−29.6%2.8% | 1.5+8.9%4.3% | 1.4+22.4%4.7% | 1.1+30.9%2.7% | 0.9—2.6% | |
| Cash from operating activities | 4.9—11.1% | −0.6−110%−1.6% | 6.1−27.9%15.4% | 8.5+33.3%20.1% | 6.3+17.1%17.6% | 5.4+77.2%14.5% | 3.1−1.8%8.9% | 3.1—10.6% | −0.6−198%−1.4% | 0.6—1.7% | |
| Capital expenditure | −0.1—−0.2% | −0.1—−0.2% | −0.3—−0.7% | −0.1—−0.2% | −0.1—−0.3% | −0.1—−0.4% | −0.2—−0.7% | −0.5—−1.6% | −0.3—−0.7% | −0.1—−0.4% | |
| Intangible assets bought | −0.1—−0.2% | −0.1—−0.3% | −0.2—−0.4% | −2.0—−4.7% | −0.3—−0.7% | −2.0—−5.3% | −0.8—−2.2% | −3.8—−13.0% | −1.2—−2.9% | −2.0—−6.1% | |
| Cash from investing activities | −4.7−8237%−10.6% | 0.1—0.2% | −0.1—−0.3% | −14—−32.5% | −0.5—−1.4% | −1.8−176%−4.7% | 2.3—6.7% | −28−391%−94.5% | 9.5—23.1% | −3.1—−9.4% | |
| Shares issued | 4.7—10.6% | — | — | — | — | — | — | — | — | — | |
| Shares bought back | −0.3—−0.6% | −0.6—−1.5% | −0.7—−1.9% | −1.1—−2.5% | −1.4—−3.9% | −1.9—−4.9% | −3.5—−10.2% | −2.9—−9.8% | −3.7—−9.1% | −2.5—−7.6% | |
| Cash from financing activities | −6.7−3526%−15.2% | 0.2—0.5% | −7.4—−18.8% | −2.1—−4.9% | −3.6—−9.9% | −7.1—−19.0% | −5.1−171%−14.8% | 7.1+266%24.3% | 1.9—4.7% | −1.1—−3.5% | |
| Change in cash | −6.5—−14.6% | −0.4—−0.9% | −1.4—−3.6% | −7.3−418%−17.3% | 2.3—6.4% | −3.5−1364%−9.2% | 0.3—0.8% | −17−260%−59.5% | 11—26.5% | −3.7—−11.2% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 34−18.2%100% | 2.2−74.0%100% | 8.8−18.8%100% | 9.1−22.0%100% | 14+31.1%100% | 8.3−8.7%100% | 11+10.0%100% | 12+37.8%100% | 10+11.6%100% | 9.1—100% | 9.8—100% | 8.5—100% | 9.4—100% | |
| Cost of revenue | — | — | — | 1.9+35.6%21.2% | 2.2*+13.4%16.4% | 1.0−25.3%11.9% | 2.0+17.6%18.6% | 1.4−9.5%12.2% | 2.0*+29.2%18.9% | 1.3—14.6% | 1.7—17.4% | 1.6—18.5% | 1.5*—16.4% | |
| Research and development | 6.5+58.6%19.1% | 0.8+30.1%39.0% | 0.8−7.8%8.8% | 1.5+12.6%16.0% | 3.4r1.5*+162%24.8% | 0.6r1.3−50.5%7.8% | 0.8r1.5−20.9%7.7% | 1.3+11.8%11.1% | 1.3*+2.2%12.4% | 1.3—14.4% | 1.1—10.8% | 1.2—13.6% | 1.3*—13.5% | |
| Selling and marketing | — | — | — | 5.1+19.7%55.5% | 6.2*+47.0%45.4% | 4.4+0.8%53.5% | 4.2−0.6%39.0% | 4.2+1.9%36.1% | 4.2*−11.3%40.5% | 4.4—48.4% | 4.2—43.1% | 4.2—48.9% | 4.8*—50.9% | |
| General and administrative | 12+10.8%35.5% | 2.2−8.2%101% | 2.5−4.1%28.9% | 2.6+3.7%28.0% | 4.7r4.0*+41.4%34.4% | 2.4r2.6−11.2%28.7% | 2.7r2.9−3.6%24.5% | 2.5+4.0%21.0% | 3.3*−3.3%31.9% | 2.7—29.4% | 2.8—28.0% | 2.4—27.9% | 3.4*—36.8% | |
| Total costs and expenses | 58+96.9%170% | 4.1+35.2%190% | 3.3−5.0%37.8% | 12+17.7%134% | 38r15*+208%277% | 3.0r10−71.9%36.5% | 3.5r12−67.8%32.3% | 10+0.5%89.0% | 12*−21.0%118% | 11—119% | 11—110% | 10—122% | 16*—166% | |
| Operating income | −9.6—−28.4% | −1.9—−89.8% | −3.2—−35.9% | −3.1−342%−34.3% | −1.4—−10.0% | −2.9r−2.0—−34.4% | −3.1r−0.7—−28.8% | 1.3—11.0% | −1.8—−17.7% | −1.7—−18.6% | −1.0—−10.4% | −1.9—−22.0% | −6.2—−66.1% | |
| Interest and finance income | 1.1+114%3.1% | 0.8+525%38.2% | 0.1−52.2%0.7% | 0.1−37.9%0.9% | 0.1*−13.8%0.7% | 0.1+90.2%1.6% | 0.1+106%1.2% | 0.1+29.9%1.1% | 0.1*+31.7%1.0% | 0.1—0.8% | 0.1—0.6% | 0.1—1.1% | 0.1*—0.9% | |
| Interest expense and finance costs | 0.6+50.2%1.7% | 0.0+15776%0.2% | 0.0+53.7%0.0% | 0.1−47.6%0.9% | 0.5r0.1*+120%3.6% | 0.0r0.1−100.0%0.0% | 0.0r0.1−99.6%0.0% | 0.2+38.2%1.4% | 0.2*+24.9%2.1% | 0.1—1.5% | 0.1—1.3% | 0.1—1.4% | 0.2*—1.9% | |
| Share of profit of associates | — | — | — | −0.1—−1.6% | — | — | — | 0—0.0% | — | — | — | — | — | |
| Income before tax | — | −1.1—−51.9% | −3.1—−35.2% | −3.1−350%−34.4% | — | −2.7r−1.9—−32.9% | −3.0r−0.7—−27.6% | 1.3—10.7% | −2.0*—−18.8% | −1.5—−16.8% | −1.1—−11.1% | −1.9—−22.3% | −6.3*—−67.1% | |
| Income tax | 0.0—0.1% | 0.0−31.7%0.2% | 0.0−31.8%0.0% | 0.0−31.7%0.0% | 0.0*—0.2% | 0.0−50.4%0.1% | 0.0−50.4%0.1% | 0.0−50.4%0.0% | −0.1*−328%−0.5% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | 0.0*—0.3% | |
| Income from discontinued operations | — | 79+9995%3659% | — | — | — | 0.8—9.4% | — | — | — | — | — | — | — | |
| Net income including minority interests | 69—204% | 78—3607% | −4.3r−4.3—−48.6% | −3.3−363%−36.0% | −1.4—−10.4% | −1.9—−23.5% | −0.7—−6.8% | 1.2—10.7% | −1.9—−18.2% | −1.5—−16.9% | −1.1—−11.2% | −1.9—−22.4% | −6.3—−67.4% | |
| Minority interests' share of net income | −0.0—−0.0% | 0.0—0.0% | 0.0−64.8%0.0% | 0.0—0.0% | −0.0*−879%−0.1% | −0.0−216%−0.1% | 0.0—0.1% | −0.0−120%−0.1% | 0.0*—0.0% | 0.0—0.1% | −0.0—−0.2% | 0.0—0.5% | −0.0*—−0.1% | |
| Net income attributable to shareholders | 69—204% | 78—3607% | −4.3—−48.6% | −3.3−362%−36.0% | −1.4—−10.3% | −1.9—−23.4% | −0.7—−6.8% | 1.3—10.7% | −1.9—−18.2% | −1.5—−17.0% | −1.1—−11.0% | −1.9—−22.9% | −6.3—−67.3% | |
| Earnings per share, basic | 4.59—— | 5.19—— | -0.29—— | -0.22−375%— | -0.09—— | -0.13—— | -0.05—— | 0.08—— | -0.14—— | -0.11—— | -0.08—— | -0.14—— | -0.44—— | |
| Earnings per share, diluted | 4.47—— | 5.07—— | -0.29—— | -0.22−375%— | -0.09—— | -0.13—— | -0.05—— | 0.08—— | -0.14—— | -0.11—— | -0.08—— | -0.14—— | -0.44—— | |
| Shares, weighted average (basic) | 15+0.2%— | 15+0.2%— | 15+0.1%— | 15+0.1%— | — | 15+6.4%— | 15+6.0%— | 15+6.0%— | — | 14—— | 14—— | 14—— | — | |
| Shares, weighted average (diluted) | 15+2.6%— | 15+2.6%— | 15+0.1%— | 15−2.0%— | — | 15+6.4%— | 15+6.0%— | 15+8.2%— | — | 14—— | 14—— | 14—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 81—70.8% | 81+430%70.8% | 3.9−76.0%6.1% | 11−27.1%15.5% | 11−36.3%14.9% | 15−13.0%23.1% | 16−7.2%23.7% | 15−18.5%21.6% | 18−2.0%23.8% | 17—22.8% | 17—22.1% | 19—22.8% | 18—22.4% | |
| Receivables | 2.1—1.9% | 2.1−79.6%1.9% | 13+30.1%21.3% | 14+36.0%20.1% | 17+44.8%22.1% | 10−7.8%15.8% | 10−11.2%15.2% | 10−1.5%15.0% | 12+19.9%15.5% | 11—14.7% | 12—14.8% | 11—13.1% | 9.8—11.9% | |
| Inventory | 0.0—0.0% | 0.0−99.0%0.0% | 0.0−99.1%0.0% | 5.5+33.1%7.7% | 0.0r6.2−99.3%0.0% | 2.9−34.9%4.5% | 3.2−25.1%4.7% | 4.1−5.3%5.9% | 4.0−13.2%5.3% | 4.5—5.9% | 4.3—5.5% | 4.3—5.3% | 4.6—5.6% | |
| Other current assets | 0.6—0.6% | 0.6−54.0%0.6% | 0.7−57.2%1.1% | 2.1−5.3%2.9% | 0.7r2.4−76.5%0.9% | 1.4−29.4%2.1% | 1.6−32.1%2.3% | 2.2−18.7%3.1% | 2.8−7.9%3.7% | 2.0—2.5% | 2.3—3.0% | 2.7—3.3% | 3.0—3.7% | |
| Current assets | 105—91.9% | 105+249%91.9% | 34+7.8%53.5% | 33+2.9%46.2% | 37+1.7%48.2% | 30−15.0%45.4% | 31−12.3%46.0% | 32−12.0%45.6% | 36+2.1%48.2% | 35—45.9% | 36—45.3% | 36—44.4% | 36—43.7% | |
| Property, plant and equipment | 0.2—0.2% | 0.2−20.9%0.2% | 0.2−16.4%0.4% | 0.2−20.5%0.3% | 0.3−4.6%0.3% | 0.3−6.0%0.4% | 0.3−11.7%0.4% | 0.3−19.1%0.4% | 0.3−24.6%0.4% | 0.3—0.4% | 0.3—0.4% | 0.4—0.5% | 0.4—0.4% | |
| Right-of-use (leased) assets | 7.2—6.3% | 7.2−5.1%6.3% | 7.3+2.2%11.6% | 7.6+6.1%10.7% | 5.8r8.3−6.4%7.5% | 7.6+21.9%11.5% | 7.1+11.9%10.5% | 7.2+10.1%10.3% | 6.2−7.5%8.2% | 6.2—8.1% | 6.4—8.1% | 6.5—8.0% | 6.7—8.2% | |
| Goodwill | — | — | — | 0.90.0%1.3% | 0.90.0%1.2% | 0.90.0%1.4% | 0.90.0%1.3% | 0.90.0%1.3% | 0.90.0%1.2% | 0.9—1.2% | 0.9—1.2% | 0.9—1.1% | 0.9—1.1% | |
| Other intangible assets | 0.0—0.0% | 0.0−99.8%0.0% | 0.0−99.7%0.1% | 13−24.7%18.0% | 0.1r14−99.7%0.1% | 15−22.7%22.8% | 16−21.9%23.5% | 17−21.1%24.3% | 18−20.5%23.8% | 19—25.3% | 20—26.1% | 22—26.4% | 23—27.6% | |
| Total assets | 114—100% | 114+72.7%100% | 63−7.4%100% | 71+1.5%100% | 77+1.6%100% | 66−14.1%100% | 68−13.5%100% | 70−14.2%100% | 76−7.6%100% | 77—100% | 79—100% | 82—100% | 82—100% | |
| Accounts payable | 17—14.5% | 17+19.3%14.5% | 20+45.4%31.1% | 17+18.7%23.3% | 19+33.4%24.2% | 14+14.7%21.0% | 13+7.5%19.8% | 14+6.5%19.9% | 14−0.9%18.4% | 12—15.7% | 13—15.9% | 13—16.0% | 14—17.2% | |
| Debt due within a year | — | — | — | — | 0−100%0.0% | — | — | — | 5.1—6.7% | — | — | — | 0—0.0% | |
| Current liabilities | 34—30.2% | 34+41.2%30.2% | 35+46.8%56.0% | 34+35.1%48.6% | 37+16.2%47.8% | 24−21.8%36.9% | 24−3.2%35.3% | 26−3.4%36.5% | 32+13.0%41.8% | 31—40.5% | 25—31.5% | 26—32.4% | 28—34.2% | |
| Lease liabilities (non-current) | 4.1—3.6% | 4.1−11.3%3.6% | 4.2−10.7%6.7% | 4.3−10.0%6.1% | 4.5−9.5%5.8% | 4.6−8.0%7.0% | 4.7−7.6%6.9% | 4.8−7.1%6.9% | 4.9−6.7%6.5% | 5.0—6.5% | 5.1—6.5% | 5.2—6.4% | 5.3—6.5% | |
| Total liabilities | 42—36.6% | 42+3.8%36.6% | 46+13.8%72.8% | 50+19.5%70.0% | 52−1.4%68.1% | 40−23.3%60.8% | 40−23.4%59.2% | 42−23.4%59.5% | 53+1.0%70.2% | 52—68.1% | 52—66.8% | 54—66.6% | 53—64.2% | |
| Retained earnings | 21—18.4% | 21—18.4% | −34—−54.7% | −30—−42.4% | −27—−34.9% | −25—−38.5% | −23—−34.5% | −23—−32.5% | −24—−31.7% | −22—−28.7% | −21—−26.1% | −19—−23.8% | −17—−21.4% | |
| Shareholders' equity | 73—63.7% | 73+178%63.7% | 17−37.7%27.7% | 22−24.5%30.5% | 25+8.9%32.4% | 26+5.4%39.6% | 28+6.2%41.2% | 29+4.2%41.0% | 23−22.8%30.2% | 25—32.3% | 26—33.6% | 27—33.7% | 30—36.2% | |
| Minority interests | −0.3—−0.3% | −0.3—−0.3% | −0.3—−0.5% | −0.3—−0.5% | −0.3—−0.4% | −0.3—−0.5% | −0.3—−0.5% | −0.3—−0.5% | −0.3—−0.4% | −0.3—−0.4% | −0.3—−0.4% | −0.3—−0.4% | −0.3—−0.4% | |
| Total equity | 72—63.4% | 72+180%63.4% | 17r17−38.2%27.2% | 21−24.8%30.0% | 25+8.9%31.9% | 26+5.4%39.2% | 28+6.3%40.8% | 28+4.2%40.5% | 23−22.9%29.8% | 24—31.9% | 26—33.2% | 27—33.4% | 29—35.8% | |
| Total liabilities and equity | 114—100% | 114+72.7%100% | 63−7.4%100% | 71+1.5%100% | 77+1.6%100% | 66−14.1%100% | 68−13.5%100% | 70−14.2%100% | 76−7.6%100% | 77—100% | 79—100% | 82—100% | 82—100% | |
| Shares outstanding | 15—— | 15+0.2%— | 15+0.2%— | 15+0.1%— | 15+7.2%— | 15+6.8%— | 15+6.2%— | 15+5.7%— | 14−1.2%— | 14—— | 14—— | 14—— | 14—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | 0.0*+40.6%1.4% | — | 1.3+23.7%14.0% | 4.0r1.0*+170%29.6% | 0.0r1.0*−98.1%0.3% | — | 1.0−10.4%8.8% | 1.5*+21.3%14.3% | 1.1*—12.3% | 1.1*—11.6% | 1.2—13.5% | 1.2*—13.2% | |
| Share-based compensation | 0.4+17.4%1.1% | 0.0*−90.1%0.4% | 0.1*−3.5%0.9% | 0.1+44.0%1.2% | 0.2*+130%1.3% | 0.1*+6.4%1.0% | 0.1*+12.1%0.7% | 0.1−5.8%0.6% | 0.1*−20.3%0.7% | 0.1*—0.8% | 0.1*—0.7% | 0.1—0.9% | 0.1*—1.0% | |
| Cash from operating activities | −0.9−114%−2.8% | −1.5*−900%−69.5% | 0.2*−80.0%1.9% | 0.4−90.1%4.2% | 0.0r0.0*−99.8%0.0% | 0.2r0.2*−60.6%2.3% | 0.8*—7.8% | 3.9—33.3% | 1.9*+83.1%18.3% | 0.5*—5.2% | −0.9*—−8.7% | −2.1—−25.1% | 1.0*—11.1% | |
| Capital expenditure | — | −0.0*—−0.5% | −0.0*—−0.4% | 0—0.0% | — | −0.0r−0.0*—−0.3% | −0.0*—−0.2% | −0.0—−0.4% | −0.0*—−0.0% | −0.0*—−0.2% | −0.0*—−0.1% | −0.0—−0.5% | −0.0*—−0.5% | |
| Intangible assets bought | — | — | — | −0.0—−0.2% | −0.1r−0.0*—−0.6% | — | — | −0.0—−0.2% | −0.0*—−0.2% | −0.0*—−0.4% | −0.0*—−0.4% | −0.0—−0.2% | −0.0*—−0.4% | |
| Cash from investing activities | 95—281% | 100*—4641% | −1.9*−774%−21.9% | −0.1—−0.7% | −3.1*—−22.5% | −0.7*−464%−8.3% | 0.3*—2.6% | −1.2—−10.5% | −0.0*−110%−0.3% | 0.2*—2.1% | −0.0*—−0.5% | −0.1—−0.7% | 0.3*—2.8% | |
| Shares issued | — | — | — | — | — | — | 0—0.0% | 4.7—40.3% | — | — | — | — | — | |
| Shares bought back | −0.3—−0.9% | −0.3*—−12.0% | 0*—0.0% | −0.1—−0.7% | 0*—0.0% | −0.0*—−0.1% | −0.0*—−0.1% | −0.2—−2.1% | −0.1*—−0.9% | −0.1*—−1.1% | −0.1*—−1.4% | −0.2—−2.9% | −0.2*—−2.0% | |
| Cash from financing activities | −29—−85.0% | −22*—−1014% | −5.4*—−61.2% | −0.8—−8.4% | −0.7*—−5.0% | −0.4*—−4.7% | −0.2*—−1.4% | −5.5−328%−47.2% | −1.4*—−13.2% | −0.5*—−5.9% | −0.3*—−3.1% | 2.4—28.5% | −1.5*—−15.9% | |
| Change in cash | 65—194% | 77*—3558% | −7.1*−830%−81.2% | −0.4—−4.8% | −3.8*−851%−27.4% | −0.9*−794%−10.7% | 1.0*—9.0% | −2.9−1359%−24.4% | 0.5*—4.8% | 0.1*—1.4% | −1.2*—−12.3% | 0.2—2.7% | −0.2*—−2.0% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Cumberland Pharmaceuticals Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$40 M91%+11%
- Sancuso$12 M27%+32%
- Kristalose$11 M24%-31%
- Vibativ$9 M21%+32%
- Caldolor$5 M10%-6.0%
- Product - Other$4 M9.3%+211%
- Other$4 M9.3%+211%
- Product - Talicia$3 M7.4%—
- Acetadote$1 M1.1%+168%
- RediTrex$0 M0.0%-89%
Countries and regions
- Non-US(total)$5 M11%+81%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Cumberland Pharmaceuticals Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025A. J. Kazimi | $2.2 M | $980 K | $341 K | $135 (peers $132) |
| 2024A. J. Kazimi | $1.1 M | $979 K | $316 K | $46 (peers $62) |
| 2023A. J. Kazimi | $980 K | $953 K | $327 K | $35 (peers $43) |
| 2022A. J. Kazimi | $583 K | $897 K | $306 K | $44 (peers $49) |
| 2021A. J. Kazimi | $1.5 M | $873 K | $412 K | $91 (peers $72) |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Cumberland Pharmaceuticals Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 1 · Directors and officers 1 · Material agreement 3 · Agreement ended 1 · New debt 1 · Shareholder vote 4 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Shareholder vote | 8-K/A | |
| Results announced | 8-K | |
| Acquisition or sale completedDirectors and officersMaterial agreementAgreement ended | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
2 acquisitions, $34 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| U.S. Product Asset Rights - Sancuso | 2022 | — | $14 M | — | Annual report |
| Product Assets And Global Rights - Vibativ | 2018 | — | $20 M | — | Annual report |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Cumberland Pharmaceuticals Inc.#
$0 spent on lobbying the US Congress and federal agencies in 2021.
Lobbying firms hired in 2021
JEFFREY J. KIMBELL AND ASSOCIATES
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2021 | $0 | — | 1 |
| 2020 | $20 K | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Cumberland Pharmaceuticals”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
FDA drug approvals: Cumberland Pharmaceuticals Inc.#
1 approved applications held; 1 approvals and 0 new uses in 2007.
| Approved | Drug | Kind |
|---|---|---|
| 2007-02-28 | VaprisolConivaptan Hydrochloride · NDA022016 | New drug (NDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (CUMBERLAND PHARMS), so they follow acquisitions
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2012 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Cumberland Pharmaceuticals Inc. compares in Pharmaceutical
- Market cap$65 M · higher than 14% of 393
- Revenue$45 M · higher than 14% of 324
- Net margin-27.4% · higher than 12% of 313
- Revenue growth17.6% · higher than 73% of 107
- Price / sales1.6× · lower than 66% of 219
- Price / book2.6× · lower than 44% of 207
- FCF yield7.4% · higher than 75% of 69
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Cumberland Pharmaceuticals Inc.🇺🇸 | $65 M | — | -27.4% | +17.6% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Korea United Pharm Inc.$191 M
- Suheung Co., Ltd.$199 M
- JW Holdings Corporation$206 M
- Hester Biosciences Limited$214 M
- Venus Remedies Limited$215 M
- Windlas Biotech Limited$217 M
Sources and freshness
- Market cap:
- Oct 27, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Cumberland Pharmaceuticals Inc.? Verify and update this profile — free
Show Cumberland Pharmaceuticals Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.